|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Otsuka America Pharmaceutical |
|---|---|
| Information provided by: | NIH AIDS Clinical Trials Information Service |
| ClinicalTrials.gov Identifier: | NCT00002129 |
Purpose
To examine the safety and tolerance of three doses of oral vesnarinone in HIV-infected patients with CD4 count > 300 cells/mm3.
| Condition | Intervention | Phase |
|---|---|---|
|
HIV Infections |
Drug: Vesnarinone |
Phase I |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3 |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Concurrent Medication:
Excluded:
Concurrent Treatment:
Excluded:
Patients with the following prior conditions are excluded:
Prior Medication:
Excluded:
Prior Treatment:
Excluded:
Active illicit drug abuse.
Contacts and Locations
More Information
| Study ID Numbers: | 234A, 22-93-251 |
| Study First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00002129 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
vesnarinone |
|
Anti-Infective Agents Sexually Transmitted Diseases, Viral Slow Virus Diseases Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Cardiotonic Agents Physiological Effects of Drugs Therapeutic Uses Retroviridae Infections RNA Virus Infections Immune System Diseases Acquired Immunodeficiency Syndrome |
Adjuvants, Immunologic Enzyme Inhibitors Cardiovascular Agents Protective Agents Antiviral Agents Immunologic Deficiency Syndromes Pharmacologic Actions Virus Diseases Phosphodiesterase Inhibitors HIV Infections Sexually Transmitted Diseases Lentivirus Infections Vesnarinone |